Nikolai Kley, Orionis Biosciences CEO
September 20, 2023 11:37 AM EDT
Deals

Genen­tech gets gluey, pay­ing $47M up­front to Ori­o­n­is for de­grad­er dis­cov­ery deal

Lei Lei Wu

News Reporter

In its sec­ond deal an­nounced Wednes­day morn­ing, Roche’s Genen­tech is sign­ing up with Ori­o­n­is Bio­sciences for a mol­e­c­u­lar glue part­ner­ship in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times